GSK (GS70) Stock Overview
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
GS70 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
GSK plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£48.80 |
| 52 Week High | UK£52.00 |
| 52 Week Low | UK£30.60 |
| Beta | 0.35 |
| 1 Month Change | 6.09% |
| 3 Month Change | 18.45% |
| 1 Year Change | 56.41% |
| 3 Year Change | 47.88% |
| 5 Year Change | 25.13% |
| Change since IPO | 40.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| GS70 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.2% | 2.5% | 0.5% |
| 1Y | 56.4% | 25.6% | 8.5% |
Return vs Industry: GS70 exceeded the German Pharmaceuticals industry which returned 25.6% over the past year.
Return vs Market: GS70 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| GS70 volatility | |
|---|---|
| GS70 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: GS70 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GS70's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 66,841 | Luke Miels | www.gsk.com |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
GSK plc Fundamentals Summary
| GS70 fundamental statistics | |
|---|---|
| Market cap | €97.88b |
| Earnings (TTM) | €6.57b |
| Revenue (TTM) | €37.56b |
Is GS70 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GS70 income statement (TTM) | |
|---|---|
| Revenue | UK£32.67b |
| Cost of Revenue | UK£8.95b |
| Gross Profit | UK£23.72b |
| Other Expenses | UK£18.00b |
| Earnings | UK£5.72b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 72.61% |
| Net Profit Margin | 17.50% |
| Debt/Equity Ratio | 106.3% |
How did GS70 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 12:02 |
| End of Day Share Price | 2026/04/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GSK plc is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |
| James Gordon | Barclays |